Immunotherapy treatments such as checkpoint-inhibiting drugs have radically improved the treatment paradigm for a range of cancers, with one notable exception: prostate tumors, which are considered “cold,” or resistant to an immune attack. Now, a team helmed by the University of Michigan Rogel Cancer Center has found a protein target that it believes could make prostate tumors amenable to immunotherapy—and a drug candidate to target it.
NEWARK, Calif.--(BUSINESS WIRE)--Aradigm Corporation (OTC PINK: ARDM) (“Aradigm” or the “Company”) announced on April 27, 2020, the Bankruptcy Court entered an order (i) conditionally approving the disclosure statement for the Combined Chapter 11 Plan and Disclosure Statement (the “Combined Plan”) filed by Aradigm Corporation (the “Company”); (ii) directing the Company to distribute the Combined Plan to creditors and shareholders for voting; and (iii) fixing April 24, 2020 as the record date for shareholders and creditors to vote.
Market Place
Share